C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $183.17 million. The enterprise value is $44.87 million.
Important Dates
The next estimated earnings date is Friday, February 27, 2026, before market open.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 96.91 million shares outstanding. The number of shares has increased by 10.42% in one year.
| Current Share Class | 96.91M |
| Shares Outstanding | 96.91M |
| Shares Change (YoY) | +10.42% |
| Shares Change (QoQ) | +2.19% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 50.80% |
| Float | 68.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.47 |
| Forward PS | 10.91 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.76, with a Debt / Equity ratio of 0.40.
| Current Ratio | 5.76 |
| Quick Ratio | 5.52 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.98% and return on invested capital (ROIC) is -28.31%.
| Return on Equity (ROE) | -59.98% |
| Return on Assets (ROA) | -23.20% |
| Return on Invested Capital (ROIC) | -28.31% |
| Return on Capital Employed (ROCE) | -51.87% |
| Weighted Average Cost of Capital (WACC) | 15.33% |
| Revenue Per Employee | $273,709 |
| Profits Per Employee | -$1.08M |
| Employee Count | 110 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.
| Income Tax | 131,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.73% in the last 52 weeks. The beta is 2.95, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.95 |
| 52-Week Price Change | -42.73% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 44.62 |
| Average Volume (20 Days) | 1,374,723 |
Short Selling Information
The latest short interest is 7.21 million, so 7.44% of the outstanding shares have been sold short.
| Short Interest | 7.21M |
| Short Previous Month | 7.38M |
| Short % of Shares Out | 7.44% |
| Short % of Float | 10.48% |
| Short Ratio (days to cover) | 4.70 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $30.11 million and -$119.08 million in losses. Loss per share was -$1.67.
| Revenue | 30.11M |
| Gross Profit | -81.66M |
| Operating Income | -119.05M |
| Pretax Income | -118.95M |
| Net Income | -119.08M |
| EBITDA | -117.04M |
| EBIT | -119.05M |
| Loss Per Share | -$1.67 |
Full Income StatementBalance Sheet
The company has $191.88 million in cash and $61.46 million in debt, with a net cash position of $138.30 million or $1.43 per share.
| Cash & Cash Equivalents | 191.88M |
| Total Debt | 61.46M |
| Net Cash | 138.30M |
| Net Cash Per Share | $1.43 |
| Equity (Book Value) | 154.41M |
| Book Value Per Share | 2.08 |
| Working Capital | 170.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$94.48 million and capital expenditures -$592,000, giving a free cash flow of -$95.07 million.
| Operating Cash Flow | -94.48M |
| Capital Expenditures | -592,000 |
| Free Cash Flow | -95.07M |
| FCF Per Share | -$0.98 |
Full Cash Flow StatementMargins
| Gross Margin | -271.23% |
| Operating Margin | -395.42% |
| Pretax Margin | -395.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.42% |
| Shareholder Yield | -10.42% |
| Earnings Yield | -65.01% |
| FCF Yield | -51.90% |
Analyst Forecast
The average price target for C4 Therapeutics is $7.25, which is 283.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.25 |
| Price Target Difference | 283.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 101.50% |
| EPS Growth Forecast (5Y) | -12.56% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -3.25 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.25 |
| Piotroski F-Score | 1 |
